Skip to main content
. 2017 Feb 15;8(13):20813–20824. doi: 10.18632/oncotarget.15343

Figure 4. An impaired binding of NuMA to α-tubulin and to kinesins HSET/kifC1 and kif18A in human cancer cells treated with PJ34.

Figure 4

NuMA was not co-immunoprecipitated with α-tubulin or kinesins HSET/kifC1 and kif18A in breast cancer cells MDA-MB-231 treated with PJ34 (20 μM, 27 h) (A and Supplementary Figure 2). No impaired binding of NuMA to α-tubulin and kinesins was detected in similarly treated human breast epithelial cells MCF10A (B). These results are schematically displayed in (C). Average 11.3 ± 1.1 times reduction in co-immunoprecipitated NuMA with α-tubulin was measured by scanning in PJ34 treated versus untreated MDA-MB-231 cancer cells. Average 1.2 ± 0.2 times reduction in the co-immunoprecipitated NuMA with α-tubulin was measured by scanning in PJ34 treated versus untreated normal epithelial cells MCF10A. Representative results of 4 different experiments are displayed.